Effect of Nintedanib on Decline in Forced Vital Capacity (FVC) in Patients With Combined Pulmonary Fibrosis and Emphysema: Data From the INBUILD Trial

被引：0
|
作者：
Cottin, V. [1 ]
Flaherty, K. R. [2 ]
Inoue, Y. [3 ]
Valenzuela, C. [4 ]
Mueller, H. [5 ]
Rohr, K. B. [6 ]
Wells, A. U. [7 ,8 ]
机构：
[1] Claude Bernard Univ Lyon 1, Louis Pradel Hosp, Hosp Civils Lyon, Natl Reference Ctr Rare Pulm Dis,UMR 754, Lyon, France
[2] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI USA
[3] Natl Hosp Org, Clin Res Ctr, Kinki Chuo Chest Med Ctr, Sakai, Osaka, Japan
[4] Univ Autonoma Madrid, Hosp Univ Princesa, Madrid, Spain
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[6] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[7] Imperial Coll, Natl Inst Hlth Res, Resp Biomed Res Unit, Royal Brompton & Harefield NHS Fdn Trust, London, England
[8] Imperial Coll, Natl Heart & Lung Inst, London, England
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2023年 / 207卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2578
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis
    Zappala, C. J.
    Latsi, P. I.
    Nicholson, A. G.
    Colby, T. V.
    Cramer, D.
    Renzoni, E. A.
    Hansell, D. M.
    du Bois, R. M.
    Wells, A. U.
    EUROPEAN RESPIRATORY JOURNAL, 2010, 35 (04) : 830 - 835
  • [42] Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
    Santermans, Eva
    Ford, Paul
    Kreuter, Michael
    Verbruggen, Nadia
    Meyvisch, Paul
    Wuyts, Wim A.
    Brown, Kevin K.
    Lederer, David J.
    Byrne, Adam J.
    Molyneaux, Philip L.
    Sivananthan, Arunon
    Moor, Catharina C.
    Maher, Toby M.
    Wijsenbeek, Marlies
    ADVANCES IN THERAPY, 2019, 36 (11) : 3059 - 3070
  • [43] Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
    Eva Santermans
    Paul Ford
    Michael Kreuter
    Nadia Verbruggen
    Paul Meyvisch
    Wim A. Wuyts
    Kevin K. Brown
    David J. Lederer
    Adam J. Byrne
    Philip L. Molyneaux
    Arunon Sivananthan
    Catharina C. Moor
    Toby M. Maher
    Marlies Wijsenbeek
    Advances in Therapy, 2019, 36 : 3059 - 3070
  • [44] Key learnings from the INBUILD trial in patients with progressive pulmonary fibrosis
    Mira-Avendano, Isabel
    Kaye, Mitchell
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2024, 18
  • [45] Prognostic impact of an early marginal decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone
    Kono, Masato
    Nakamura, Yutaro
    Enomoto, Noriyuki
    Saito, Go
    Koyanagi, Yu
    Miyashita, Koichi
    Tsutsumi, Akari
    Kobayashi, Takeshi
    Yasui, Hideki
    Hozumi, Hironao
    Karayama, Masato
    Suzuki, Yuzo
    Furuhashi, Kazuki
    Miki, Yoshihiro
    Hashimoto, Dai
    Fujisawa, Tomoyuki
    Inui, Naoki
    Suda, Takafumi
    Nakamura, Hidenori
    RESPIRATORY INVESTIGATION, 2019, 57 (06) : 552 - 560
  • [46] Decline in Forced Vital Capacity (FVC) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) with and without Cough: Data from the SENSCIS Trial
    Kreuter, M.
    Volkmann, E. R.
    Hoffmann-Vold, A.
    Wijsenbeek, M. S.
    Smith, V.
    Khanna, D.
    Denton, C. P.
    Wuyts, W. A.
    Stock, C.
    Alves, M.
    Sambevski, S.
    Allanore, Y.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [47] Decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) with and without dyspnoea: data from the SENSCIS trial
    Kreuter, M.
    Volkmann, R. E.
    Hoffmann-Vold, A.
    Wijsenbeek, S. M.
    Smith, V
    Khanna, D.
    Denton, P. C.
    Wuyts, A. W.
    Miede, C.
    Alves, M.
    Sambevski, S.
    Allanore, Y.
    PNEUMOLOGIE, 2022, 76 : S19 - S20
  • [48] Decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) with and without cough: data from the SENSCIS trial
    Kreuter, M.
    Volkmann, R. E.
    Hoffmann-Vold, A.
    Wijsenbeek, S. M.
    Smith, V
    Khanna, D.
    Denton, P. C.
    Wuyts, A. W.
    Stock, C.
    Alves, M.
    Sambevski, S.
    Allanore, Y.
    PNEUMOLOGIE, 2022, 76 : S19 - S19
  • [49] DECLINE IN FORCED VITAL CAPACITY (FVC) IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) WITH AND WITHOUT DYSPNOEA: DATA FROM THE SENSCIS TRIAL
    Volkmann, E.
    Kreuter, M.
    Hoffmann-Vold, A. M.
    Wijsenbeek, M.
    Smith, V.
    Khanna, D.
    Denton, C.
    Wuyts, W.
    Miede, C.
    Alves, M.
    Sambevski, S.
    Allanore, Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 101 - 102
  • [50] Effect of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis and Differing Extents of Emphysema on HRCT
    Cottin, V.
    Jacob, J.
    Sverzellati, N.
    Richeldi, L.
    Bendstrup, E.
    Stowasser, S.
    Lievens, D.
    Stansen, W.
    Wells, A. U.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
12345